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https://upload.wikimedia.org/wikipedia/commons/b/b4/Aortic_stenosis_rheumatic,_gross_pathology_20G0014_lores.jpg 
Definition  
Valvular heart disease (VHD) is any disease process involving 
one or more of the four valves of the 
heart (the aortic and mitral valves on the left and 
the pulmonary and tricuspid valves on the right).  
There are two types of heart valve disease: 
• Valvular stenosis, that occurs when a heart valve doesn't 
fully open due to stiff or fused leaflets.   
• Valvular insufficiency (regurgitation, incompetence, "leaky 
valve“), that occurs when a valve does not close tightly  
 
http://www.webmd.com/heart-disease/guide/heart-valve-disease https://en.wikipedia.org/wiki/Valvular_heart_disease 
Epidemiology   
  
http://www.nature.com/nrcardio/journal/v8/n3/fig_tab/nrcardio.2010.202_ft.html https://en.wikipedia.org/wiki/Valvular_heart_disease 
• Valvular heart disease 
occur largely as a result 
of aging.  
• Most people are in their 
late 50s when 
diagnosed, and more 
than one in ten people 
over 75 have it. 
• Abbreviation: AR, aortic 
regurgitation; AS, aortic 
stenosis; M, multiple 
valve disease; MR, 
mitral regurgitation; 
MS, mitral stenosis; R, 
right-sided heart 
disease. 
Risk Factors and Etiology   
• Aortic stenosis: calcification of tricuspid aortic valve with age, calcification 
of bicuspid aortic valve, rheumatic fever. 
• Aortic regurgitation: 1) acute: infective endocarditis, trauma; 2) chronic: 
2a) primary valvular: rheumatic fever, bicuspid aortic valve, Marfan's 
syndrome, Ehlers–Danlos syndrome, ankylosing spondylitis, systemic lupus 
erythematosus; 2b) disease of the aortic root: syphilitic 
aortitis, osteogenesis imperfecta, aortic dissection, Behçet's disease, 
reactive arthritis, systemic hypertension. 
• Mitral stenosis: almost always caused by rheumatic heart disease. 
• Mitral regurgitation: 1) acute: endocarditis, mainly S. aureus, papillary 
muscle rupture or dysfunction, including mitral valve prolapse; 2) chronic: 
rheumatic fever, Marfan's syndrome, cardiomyopathy. 
• Tricuspid regurgitation: 1) secondary to right ventricular dilation; 2) Other 
causes: tricuspid endocarditis, rheumatic fever, Ebstein's anomaly, 
carcinoid syndrome and myxomatous degeneration. 
https://en.wikipedia.org/wiki/Valvular_heart_disease 
Mechanisms 
• Aortic stenosis: obstruction through the aortic ostium causes increased 
pressure in the LV and impaired flow through the aorta. 
• Aortic regurgitation: insufficiency of the aortic valve causes backflow of 
blood into the LV during diastole. 
• Mitral stenosis:  progressive obstruction of the mitral ostium causes 
increased pressure in the left atrium and the pulmonary circulation; 
congestion may cause thromboembolism, and atrial hypertension may 
cause atrial fibrillation. 
• Mitral regurgitation: insufficiency of the mitral valve causes backflow of 
blood into the left atrium during systole. 
• Tricuspid regurgitation: insufficiency of the tricuspid valve causes backflow 
of blood into the right atrium during systole. 
https://en.wikipedia.org/wiki/Valvular_heart_disease 
Mechanisms 
(Accents on Inflammation) 
http://circresearch.com/gallery/fibrocalcific-aortic-valve-disease-opportunity-to-understand-disease-mechanisms-using-mouse-models/ 
Classification 
(International Classification of Diseases (ICD) 
apps.who.int/classifications/icd10/browse/2016/en#/I46 
 
I34 Nonrheumatic mitral valve disorder 
I35 Nonrheumatic aortic valve disorders 
I36 Nonrheumatic tricuspid valve disorders 
I37 Pulmonary valve disorders 
I38 Endocarditis, valve unspecified 
I39* Endocarditis and heart valve disorders in diseases 
classified elsewhere 
Q22 Congenital malformations of pulmonary and tricuspid 
valves 
Q23 Congenital malformations of aortic and mitral valves 
Q24 Other congenital malformations of heart 
Q25 Congenital malformations of great arteries 
Classification 
(Types) 
https://en.wikipedia.org/wiki/Valvular_heart_disease 
Valve involved Stenotic disease 
Insufficiency/regurgitation 
disease 
Aortic valve Aortic valve stenosis (AS) 
Aortic 
insufficiency/regurgitation (AR) 
 
Mitral valve Mitral valve stenosis (MS) 
Mitral 
insufficiency/regurgitation 
(MR) 
Tricuspid valve Tricuspid valve stenosis 
Tricuspid 
insufficiency/regurgitation 
Pulmonary valve Pulmonary valve stenosis 
Pulmonary 
insufficiency/regurgitation 
Classification 
(Stages of Progression of VHD) 
http://content.onlinejacc.org/article.aspx?articleid=1838843 
Stage Definition Description 
A At risk Patients with risk factors for development of VHD 
B Progressive 
Patients with progressive VHD (mild-to-moderate 
severity and asymptomatic) 
C 
Asymptomatic 
severe 
Asymptomatic patients who have the criteria for 
severe VHD: 
C1: Asymptomatic patients with severe VHD in 
whom the left or right ventricle remains 
compensated 
C2: Asymptomatic patients with severe VHD with 
decompensation of the left or right ventricle 
D 
Symptomatic 
severe 
Patients who have developed symptoms as a 
result of VHD 
Clinical Investigation 
• Aortic stenosis: heart failure symptoms; angina pectoris; syncope, 
usually exertional. 
• Aortic regurgitation: heart failure symptoms; palpitations; angina 
pectoris; in acute cases: cyanosis and circulatory shock. 
• Mitral stenosis: heart failure symptoms. 
• Mitral regurgitation: heart failure symptoms; palpitations; 
pulmonary edema. 
• Tricuspid regurgitation: symptoms of right-sided heart failure 
(ascites, hepatomegaly, edema, jugular venous distension, and atc.). 
https://en.wikipedia.org/wiki/Valvular_heart_disease 
Diagnosis 
• Aortic stenosis: chest X-ray (calcific aortic valve, enlarged LV and atrium); 
ECG (LV hypertrophy and left atrial abnormality; echocardiography (LV 
hypertrophy, thickened and immobile aortic valve and dilated aortic root); 
cardiac chamber catheterization (stenosis in valve area ). 
•  Aortic regurgitation: chest X-ray (LV hypertrophy, dilated aorta); ECG (LV 
hypertrophy); echocardiogram (dilated left aortic root and reversal of 
blood flow in the aorta). 
• Mitral stenosis: chest X-ray (left atrial enlargement); echocardiography 
(left atrial enlargement, thick and calcified mitral valve with narrow and 
"fish-mouth"-shaped orifice and signs of right ventricular failure in 
advanced disease). 
• Mitral regurgitation: chest X-ray (dilated LV); echocardiography (mitral 
reverse flow, dilated left atrium and LV with decreased LV function). 
• Tricuspid regurgitation: echocardiography (tricuspid prolapse or flail), 
ECG (enlargement of RV and atrium). 
 
https://en.wikipedia.org/wiki/Valvular_heart_disease 
Diagnosis 
(Echocardiographic Criteria for the Definition of 
Severe Valve Stenosis)  
https://eurheartj.oxfordjournals.org/content/ehj/33/19/2451.full.pdf 
Diagnosis 
(Echocardiographic Criteria for the Definition of 
Severe Valve Regurgitation)  
https://eurheartj.oxfordjournals.org/content/ehj/33/19/2451.full.pdf 
Diagnosis 
(Aortic Stenosis ) 
http://www.inventivemedical.com/wp-content/uploads/2014/10/Pathology-4-aortic-stenosis-Doppler-1.png https://en.wikipedia.org/wiki/Valvular_heart_disease 
Diagnosis 
(Aortic Regurgitation) 
http://1.bp.blogspot.com/-RJ1nkDRY6Rc/TzJPB9zVHsI/AAAAAAAADqM/9tzJ5p0XUJA/s1600/Obraz1.jpg http://www.heart-vessels.com/images/aortic-insufficiency.jpg 
Diagnosis 
(Mitral Stenosis ) 
content.onlinejacc.org/data/Journals/JAC/928699/81619_gr4.jpeg clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/mitral-valve-disease/images/figure-8.jpg 
Diagnosis 
(Mitral Regurgitation) 
herzzentrum.immanuel.de/fileadmin/user_upload/IK_Bernau/03_Abteilungen/03_07_Herzzentrum/03_07_02_Leistungen/02_1_Krankheitsbilder  
Diagnosis 
(Tricuspid Regurgitation) 
http://bestpractice.bmj.com/best-practice/images/bp/en-gb/472-2_default.jpg 
Treatment 
(Aortic Stenosis) 
• No treatment in asymptomatic patients. 
• If symptomatic, treated with aortic valve replacement surgery. 
• Medical therapy and percutaneous balloon valvuloplasty have 
relatively poor effect: 
- any angina is treated with short-acting nitrovasodilators, beta-
blockers and/or calcium blockers; 
- any hypertension is treated aggressively, but caution must be 
taken in administering beta-blockers; 
- Any heart failure is treated with diuretics, nitrovasodilators 
and, if not contraindicated, cautious inpatient administration of 
ACE inhibitors. 
https://en.wikipedia.org/wiki/Valvular_heart_disease 
Treatment 
(Aortic Regurgitation) 
• If stable and asymptomatic - conservative treatment such 
as low sodium diet, diuretics, vasodilators (e.g. (hydralazin or 
prazosin), ACE inhibitors/angiotensin II receptor 
antagonists, calcium blockers and avoiding very strenuous 
activity. 
• Aortic valve replacement in symptomatic patients (NYHA II-IV) 
or progressive LV dilation or systolic ventricular diameter 
>55 mm on echocardiography, immediately if acute. 
• Endocarditis prophylaxis is indicated before dental, 
gastrointestinal or genitourinary procedures.  
https://en.wikipedia.org/wiki/Valvular_heart_disease 
Treatment 
(Mitral Stenosis) 
• No therapy is required for asymptomatic patients.  
• Diuretics for any pulmonary congestion or edema. 
• If stenosis is severe, surgery is recommended. 
• Any atrial fibrillation is treated accordingly (rate or rrhythm 
control, and chronic anticoagulant administration). 
• Prophylaxis of infective endocarditis . 
• Surgically, by mitral valvuloplasty with a percutaneously 
inserted balloon, unless significant mitral regurgitation or too 
much calcification (indicated in ostium area < 1-1.2 cm2). 
• Other options include valvulotomy or mitral valve 
replacement by open surgery. 
https://en.wikipedia.org/wiki/Valvular_heart_disease 
Treatment 
(Mitral Regurgitation) 
• Medically:  
• afterload reduction with vasodilators; 
• any hypertension is treated aggressively, e.g. 
by diuretics and low sodium diet; 
• antiarrhythmics; 
• chronic anticoagulation in concomitant mitral valve 
prolapse or atrial fibrillation. 
• In acute cases - intra-aortic balloon pump (IABP) as temporary 
solution until surgery. 
• Surgery by either mitral valve repair or mitral valve 
replacement, indicated if very symptomatic (NYHA III), 
ventricular dilation or decreasing ejection fraction. 
https://en.wikipedia.org/wiki/Valvular_heart_disease 
Treatment 
(Tricuspid Regurgitation) 
• Treatment of underlying cause. 
• Surgery: 
– tricuspid valvular repair; 
– Valvuloplasty; 
– valve replacement(rarely performed). 
https://en.wikipedia.org/wiki/Valvular_heart_disease 
Treatment 
(Prosthetic Heart Valves) 
• Bioprosthetic valves used in heart 
valve replacement generally offer 
functional properties (e.g., 
hemodynamics, resistance to 
thrombosis) that are more similar 
to those of native valves.  
• Implantation of prosthetic cardiac 
valves to treat hemodynamically 
significant aortic or mitral valve 
disease has become increasingly 
common. 
http://emedicine.medscape.com/article/780702-overview 
Treatment 
(Prosthetic Heart Valves Malfunction) 
• Acute prosthetic valve failure: sudden onset of dyspnea, 
syncope, or precordial pain. 
• Acute aortic valve failure: sudden death; survivors have acute 
severe dyspnea, sometimes accompanied by precordial pain, 
or syncope. 
• Subacute valvular failure: symptoms of gradually worsening 
congestive heart failure; they also may present with unstable 
angina or, at times, may be entirely asymptomatic. 
• Embolic complications: symptoms related to the site of 
embolization (e.g., stroke, myocardial infarction, sudden 
death, or symptoms of visceral or peripheral embolization). 
• Anticoagulant-related hemorrhage: symptoms related to the 
site of hemorrhage. 
http://emedicine.medscape.com/article/780702-overview 
Prognosis  
• The prognosis for patients with valvular heart disease has 
improved substantially over the past 15 years.  
• A better understanding of the proper timing of surgery is one 
of the key reasons.  
• In general, surgery for stenotic valvular disease can be 
delayed until symptoms appear.  
• Conversely, in regurgitant valvular heart disease, 
prognostically important left ventricular dysfunction may 
develop in the absence of symptoms, and thus valve surgery 
for some asymptomatic patients is entirely appropriate.  
http://www.nejm.org/doi/full/10.1056/NEJM199707033370107 
Prophylaxis 
• Prompt treatment of strep infections can prevent rheumatic 
fever, which damages the heart valves. 
• An exercise, a heart-healthy diet, and medicines that lower 
cholesterol might prevent aortic stenosis (thickening and 
stiffening of the aortic valve).   
• Heart-healthy eating, physical activity, other heart-healthy 
lifestyle changes, and medicines aimed at preventing a heart 
attack, high blood pressure, or heart failure also may help 
prevent heart valve disease. 
https://www.nhlbi.nih.gov/health/health-topics/topics/hvd/prevention 
Abbreviations  
ACE - angiotensin converting 
enzyme 
AR – aortic regurgitation 
AS - aortic valve stenosis  
ECG - electrocardiogram  
ERO - effective regurgitant 
orifice 
IABP - intra-aortic balloon 
pump 
IE - infective endocarditis 
LA  - left atrium 
 
  
LVEF - left ventricular ejection 
fraction 
LVESD - left ventricular end-
systolic dimension 
MS - mitral valve stenosis  
MVA - mitral valve area 
PAWP pulmonary artery wedge 
pressure 
MR – mitral regurgitation 
PR – pulmonary 
regurgitation 
VHD - valvular heart disease  
 
Diagnostic and treatment guidelines 
2014 AHA/ACC Guideline for the Management of Patients With 
Valvular Heart Disease 
Guidelines on the management of valvular heart disease (version 
2012) 
Prosthetic Heart Valves 
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https://mileon.files.wordpress.com/2010/07/sin-titulo4.png 
Definition  
Infective endocarditis (IE) is a potentially lethal disease 
caused largely by bacteria that enter the bloodstream and 
settle in the heart, which may include one or more heart 
valves, the mural endocardium, or a septal defect or a blood 
vessel, with intracardiac effects that include severe valvular 
insufficiency and intractable congestive heart failure and 
myocardial abscesses.   
emedicine.medscape.com/article/216650-overview circ.ahajournals.org/content/early/2015/09/15/CIR.0000000000000296 
Epidemiology   
  
http://circ.ahajournals.org/content/early/2015/09/15/CIR.0000000000000296 
• IE is an uncommon infectious disease with an annual 
incidence ranging from 3 to 7 per 100000 person-years in the 
most contemporary population surveys. 
• Although relatively rare, IE continues to be characterized by 
increased morbidity and mortality and is now the third or 
fourth most common life-threatening infection syndrome, 
after sepsis, pneumonia, and intra-abdominal abscess.  
• Characteristics of IE patients have shifted toward an increased 
mean patient age, a higher proportion of prosthetic valves 
and other cardiac devices, and a decreasing proportion of 
rheumatic heart disease.  
• The proportion of IE patients undergoing surgery has 
increased over time to reach ≈50%. 
Risk Factors 
• Artificial heart valves. 
• Intracardiac devices. 
• Unrepaired cyanotic congenital heart defects. 
• History of infective endocarditis. 
• Chronic rheumatic heart disease.  
• Age-related degenerative valvular lesions. 
• Hemodialysis. 
• Coexisting conditions, especially ones that suppress immunity 
(diabetes mellitus, alcohol abuse, HIV/AIDS, and intravenous 
drug). 
•  Etc. 
https://en.wikipedia.org/wiki/Infective_endocarditis 
Etiology   
• Many microorganisms can cause infective endocarditis.  
• These are generally isolated by blood culture, where the 
patient's blood is removed, and any growth is noted and 
identified.  
• The term bacterial endocarditis (BE) commonly is used, 
reflecting the fact that most cases of IE are due to bacteria; 
however, infective endocarditis (IE) has become the preferred 
term. 
https://en.wikipedia.org/wiki/Infective_endocarditis 
Etiology 
(Bacterial) 
• Staphylococcus aureus followed by Streptococci of the 
viridans group and coagulase negative Staphylococci are the 
three most common organisms responsible for infective 
endocarditis.  
• Other Streptococci and Enterococci are also a frequent cause 
of infective endocarditis.   
• Enterococcus can enter the bloodstream as a consequence of 
abnormalities in the gastrointestinal or genitourinary tracts. 
• Some organisms, when isolated, give valuable clues to the 
cause, as they tend to be specific. 
• Less commonly reported etiological bacteria are 
Pseudomonas, S. bovis, Clostridium septicum, 
Bartonella, Chlamydia psittaci, Coxiella etc.  
https://en.wikipedia.org/wiki/Myocarditis#Causes 
Etiology 
(Fungal) 
• Candida albicans, a yeast, is associated with endocarditis in 
IV drug users and immunocompromised patients. 
• Other fungi demonstrated to cause endocarditis 
are Histoplasma capsulatum and Aspergillus. 
• Endocarditis with Tricosporon asahii has also been reported. 
https://en.wikipedia.org/wiki/Myocarditis#Causes 
Mechanisms  
http://emedicine.medscape.com/article/216650-overview#a3 https://en.wikipedia.org/wiki/Myocarditis#Causes 
• Damaged valves and endocardium contribute to the development of IE. 
• The damaged part of a heart valve forms a local blood clot, a condition 
known as non-bacterial thrombotic endocarditis (NBTE); the platelet 
and fibrin deposits that form as part of the blood clotting process allow 
bacteria to take hold and form vegetations. 
• Damage to the valves and endocardium can be caused by altered, 
turbulent blood flow, more likely in high pressure areas; catheters, 
electrodes, and other intracardiac prosthetic devices; solid particles 
from repeated intravenous injections, chronic inflammation.  
• The complications of acute BE result from intracardiac disease and 
metastatic infection produced by suppurative emboli.  
• Because of their shortened course, immunological phenomena are not 
a part of acute IE. 
Mechanisms     
(pathogen–host interaction and risk states) 
http://www.nature.com/nrcardio/journal/v11/n1/fig_tab/nrcardio.2013.174_F1.html 
Classification 
(International Classification of Diseases (ICD)) 
apps.who.int/classifications/icd10/browse/2016/en#/I46 
 
133 Acute and subacute endocarditis 
 I33.0 Acute and subacute infective endocarditis 
           Endocarditis (acute)(subacute):bacterial  
  infective NOS 
  lenta 
  malignant 
  septic 
  ulcerative. 
  I33.9 Acute endocarditis, unspecified. 
 
Classification 
(the Rate of Progression and Severity of Disease) 
http://www.merckmanuals.com/professional/cardiovascular-disorders/endocarditis/infective-endocarditis https://en.wikipedia.org/wiki/Infective_endocarditis 
• Subacute bacterial endocarditis (SBE) is often due to streptococci of low 
virulence (mainly viridans streptococci) and mild to moderate illness which 
progresses slowly over weeks and months and has low propensity to 
hematogenously seed extracardiac sites. 
• Acute bacterial endocarditis (ABE) is a fulminant illness over days to 
weeks, and is more likely due to Staphylococcus aureus which has much 
greater virulence, or disease-producing capacity and frequently causes 
metastatic infection. 
• Prosthetic valvular endocarditis (PVE) develops in 2 to 3% of patients 
within 1 yr. after valve replacement and in 0.5%/yr. thereafter.   
• The terms short incubation (meaning less than about six weeks), and long 
incubation (greater than about six weeks) are preferred. 
Clinical Investigation  
(Signs and Symptoms) 
• Fever (97% of patients), malaise and endurance fatigue (90% of 
patients). 
• A new or changing heart murmur, weight loss, and coughing 
(35% of patients).  
• Vascular phenomena: septic embolism (causing 
stroke or gangrene of fingers), Janeway lesions (painless 
hemorrhagic cutaneous lesions on the palms and soles), 
intracranial hemorrhage, conjunctival and splinter hemorrhages, 
kidney and splenic infarcts. 
• Immunologic phenomena: glomerulonephritis , Osler's 
nodes (painful subcutaneous lesions in the distal fingers), Roth's 
spots on the retina, positive serum rheumatoid factor) 
• Other signs: night sweats, rigors, anemia, etc. 
https://en.wikipedia.org/wiki/Infective_endocarditis 
Clinical Investigation  
(Janeway lesions) 
https://s-media-cache-ak0.pinimg.com/736x/89/bc/e9/89bce950c573e31574d2ebf4731ec3a7.jpg 
Clinical Investigation  
(Skin Lesions) 
http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/infectious-disease/infective-endocarditis/ 
Clinical Investigation  
(Osler's Nodes) 
http://yxzl.baiduyy.com/chm11/jzyxtp/Ch.13_files/image012.jpg 
Clinical Investigation  
(Roth's spots) 
http://medlibes.com/uploads/Screen%20shot%202010-07-17%20at%205.12.22%20PM.png 
Clinical Investigation  
(Sub-acute IE clinical symptoms) 
http://image.slidesharecdn.com/infectiveendocarditis-130201001609-phpapp02/95/infective-endocarditis-11-638.jpg?cb=1359678043 
Diagnosis 
http://circ.ahajournals.org/content/early/2015/09/15/CIR.0000000000000296 
• The diagnosis of IE is straightforward in the minority of patients who present 
with a consistent history and classic oslerian manifestations: sustained 
bacteremia or fungemia, evidence of active valvulitis, peripheral emboli, and 
immunological vascular phenomena.  
• In most patients, however, the “textbook” history and physical examination 
findings may be few or absent.  
• Acute IE may evolve too quickly for the development of immunological vascular 
phenomena, which are more characteristic of the later stages of the more 
insidious subacute form of untreated IE.  
• The variability in clinical presentation of IE and the importance of early 
accurate diagnosis require a diagnostic strategy that is both sensitive for 
disease detection and specific for its exclusion across all forms of the disease.  
• In 1994, Durack and colleagues23 from the Duke University Medical Center 
proposed a diagnostic schema that stratified patients with suspected IE into 3 
categories: definite, possible, and rejected cases. 
Diagnosis 
(the Modified Duke Criteria: Definite, Possible, 
and Rejected Cases) 
http://circ.ahajournals.org/content/early/2015/09/15/CIR.0000000000000296 
Definite IE  
 Pathological criteria: microorganisms demonstrated by culture or 
histological examination of a vegetation, a vegetation that has embolized, or an 
intracardiac abscess specimen; or pathological lesions; vegetation or intracardiac 
abscess confirmed by histological examination showing active endocarditis. 
  Clinical criteria: 2 Major criteria, 1 major criterion and 3 minor criteria, or 
5 minor criteria  
Possible IE  
 1 Major criterion and 1 minor criterion, or 3 minor criteria  
Rejected  
 Firm alternative diagnosis explaining evidence of IE; or resolution of IE 
syndrome with antibiotic therapy for ≤4 d; or no pathological evidence of IE at 
surgery or autopsy with antibiotic therapy for ≤4 d; or does not meet criteria for 
possible  
IE as above IE indicates infective endocarditis.  
Diagnosis 
(the Modified Duke Criteria: Major Criteria)  
http://circ.ahajournals.org/content/early/2015/09/15/CIR.0000000000000296 
Blood culture positive for IE (2 separate blood cultures: Viridans 
streptococci, Streptococcus bovis, HACEK (Haemophilus species, 
Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, 
and Kingella species) group, Staphylococcus aureus; or community-
acquired enterococci in the absence of a primary focus, or microorganisms 
consistent with IE from persistently positive blood cultures defined as 
follows: at least 2 positive cultures of blood samples drawn >12 h apart or 
all 3 or a majority of ≥4 separate cultures of blood (with first and last 
sample drawn at least 1 h apart).  
Single positive blood culture for Coxiella burnetii or anti–phase 1 IgG 
antibody titer ≥1:800.  
Evidence of endocardial involvement  (echocardiogram positive for IE (TEE 
recommended for patients with prosthetic valves, rated at least possible IE 
by clinical criteria, or complicated IE).  
Diagnosis 
(the Modified Duke Criteria: Minor Criteria)  
http://circ.ahajournals.org/content/early/2015/09/15/CIR.0000000000000296 
Predisposition, predisposing heart condition, or IDU (injection drug 
use) 
Fever, temperature >38°C. 
Vascular phenomena, major arterial emboli, septic pulmonary 
infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival 
hemorrhages, and Janeway lesions. 
Immunological phenomena: glomerulonephritis, Osler nodes, Roth 
spots, and rheumatoid factor. 
Microbiological evidence: positive blood culture but does not meet 
a major criterion as noted above (excludes single positive cultures 
for coagulase negative staphylococci and organisms that do not 
cause endocarditis) or serological evidence of active infection with 
organism consistent with IE. 
Diagnosis 
(Laboratory Investigations and Biomarkers)  
http://eurheartj.oxfordjournals.org/content/early/2015/08/28/eurheartj.ehv319 
• Sepsis severity may be indicated by the demonstration of a 
number of laboratory investigations, including the degree of 
leucocytosis/leucopoenia, the number of immature white cell 
forms, concentrations of C-reactive protein (CRP) and 
procalcitonin, erythrocyte sedimentation rate (ESR) and markers 
of end-organ dysfunction (lactataemia, elevated bilirubin, 
thrombocytopenia and changes in serum creatinine 
concentration); however, none are diagnostic for IE. 
• Further, certain laboratory investigations are used in surgical 
scoring systems relevant to risk stratification in patients with IE, 
including bilirubin, creatinine and platelet count and creatinine 
clearance.  
• The pattern of increase in inflammatory mediators or immune 
complexes may support, but not prove, the diagnosis of IE.   
Diagnosis 
(Imaging Techniques)  
http://eurheartj.oxfordjournals.org/content/early/2015/08/28/eurheartj.ehv319 
• Imaging plays a key role in both the diagnosis and management of 
IE.  
• Echocardiography is useful for the prognostic assessment of 
patients with IE, for its follow-up under therapy and during and 
after surgery. 
• Echocardiography is particularly useful for initial assessment of the 
embolic risk and in decision making in IE.  
• Transoesophageal echocardiography (TEE) plays a major role both 
before and during surgery (intraoperative echocardiography).  
• The evaluation of patients with IE is no longer limited to 
conventional echocardiography, but should include several other 
imaging techniques such as magnetic resonance imaging 
(MRI), positron emission tomography (PET)/computed tomography 
(CT), etc. 
Diagnosis 
(Echocardiography as the Reference Method)  
http://eurheartj.oxfordjournals.org/content/35/10/624 
Large vegetation on the posterior mitral leaflet (arrow) (transoesophageal 
echocardiography) (A) two-dimensional transoesophageal 
echocardiography —(B) three-dimensional transoesophageal 
echocardiography. LA, left atrium; LV, left ventricle; Ao, aorta; AML, 
anterior mitral leaflet; PML, posterior mitral leaflet. 
Diagnosis 
(Cardiac Computed Tomography)  
https://bjcardio.co.uk/2012/03/aortic-root-fistula-complicating-infective-endocarditis-role-of-64-multi-detector-ct-cardiac-angiography/ 
Cardiac computed tomography (CT) multi-planar reconstruction. The abscess 
cavity (hollow arrow) communicates with the aortic root (F1) and LV outflow 
tract (F2) to form a fistula. The abscess presses forward into the right ventricular 
outflow tract displacing the pulmonary valve (PV) superiorly. B: Cardiac CT blood 
pool inversion image. The bicuspid aortic valve (AV) is clearly seen with a 
fistulous connection (F1) to the abscess cavity (hollow arrow) 
Diagnosis 
(the Diagnostic Use of Echocardiography)  
http://circ.ahajournals.org/content/early/2015/09/15/CIR.0000000000000296 
Diagnosis 
(Differential)  
http://patient.info/doctor/systemic-lupus-erythematosus-pro 
• Systemic Lupus Erythematosus. 
• Cardiac tumours, e.g. atrial myxoma. 
• Lyme disease. 
• Antiphospholipid syndrome. 
• Polymyalgia rheumatica. 
• Reactive arthritis. 
Treatment 
(Antimicrobial Therapy: Principles) 
• The primary goal of antibiotic treatment is to eradicate 
infection, including sterilizing vegetations, although the unique 
characteristics of infected vegetations (focal infection with high 
bacterial density, slow rate of bacterial growth within biofilms, 
and low microorganism metabolic activity, impaired immunity ) 
can pose a variety of challenges.  
• Antibiotics may fail to eradicate infection as a result of 
increased binding of the drug to serum proteins, perturbations 
of antibiotic penetration into the vegetation, and unique 
antibiotic pharmacokinetic/pharmacodynamic (PK/PD) features. 
• Therefore, prolonged, parenteral, bactericidal therapy is 
required for attempted infection cure. 
http://circ.ahajournals.org/content/early/2015/09/15/CIR.0000000000000296 
Treatment 
(Antimicrobial Therapy: Inoculum Effect) 
• The effect of high bacterial densities on antimicrobial activity is 
called the inoculum effect in which certain groups of 
antimicrobials commonly used to treat IE such as β-lactams and 
glycopeptides (and, to a lesser extent, lipopeptides such as 
daptomycin) are less active against highly dense bacterial 
populations. 
• The effective minimum inhibitory concentration (MIC) at the 
site of infection with bacterial densities of 108 to 1011 colony-
forming units per 1 g tissue can be much higher than 
anticipated by in vitro susceptibility tests that use a standard 
inoculum (105.5 colony-forming units per milliliter).  
 
http://circ.ahajournals.org/content/early/2015/09/15/CIR.0000000000000296 
Treatment 
(Antimicrobial Therapy: Bactericidal Drugs) 
• Data from clinical investigations support the need for 
bactericidal antibiotics to sterilize vegetations in IE with high 
bacterial densities. 
• For enterococci, bactericidal activity can be achieved by the 
combination of certain β-lactam antibiotics (e.g., penicillin, 
ampicillin, and piperacillin) with an aminoglycoside.  
• The bactericidal effect achieved by a combination of 
antibacterial drugs that alone only inhibit bacterial growth is 
called synergy.  
• The rate of bactericidal activity against some other organisms 
can also be enhanced by a combination of a β-lactam antibiotic 
plus an aminoglycoside. 
http://circ.ahajournals.org/content/early/2015/09/15/CIR.0000000000000296 
Treatment 
(Antimicrobial Therapy: Duration) 
• The duration of therapy in IE must be sufficient to ensure complete 
eradication of microorganisms within vegetations.  
• When the bactericidal activity is known to be more rapid or the likely 
vegetation bacterial burden is lower, then the clinician may prescribe 
a shorter duration of antimicrobial therapy in unique instances.  
• Combination therapy with penicillin or ceftriaxone and an 
aminoglycoside for 2 weeks is highly effective in viridans group 
streptococci (VGS) IE in very select patients with uncomplicated 
infection.  
• Both β-lactam therapy alone and combination therapy with nafcillin 
and an aminoglycoside for only 2 weeks have been effective in 
patients with uncomplicated right-sided IE caused by S aureus; 
monotherapy with a β-lactam would be selected for use in cases of 
uncomplicated IE.  
http://circ.ahajournals.org/content/early/2015/09/15/CIR.0000000000000296 
Treatment 
(Fungi) 
• Fungal IE is rare but can develop in a wide range of patients. 
• A 2-phase treatment of fungal IE has evolved. The initial or 
induction phase consists of control of infection. Treatment 
includes a combination of a parenteral antifungal agent, 
usually an amphotericin B–containing product, and valve 
surgery.  
• Antifungal therapy usually is given for >6 weeks. 
 
http://circ.ahajournals.org/content/early/2015/09/15/CIR.0000000000000296 
Treatment 
(Long-Term Follow-Up) 
• Months to years after completion of medical therapy for IE, 
patients should have ongoing observation for and education 
about recurrent infection and delayed onset of worsening 
valve dysfunction. 
• Daily dental hygiene should be stressed, with serial 
evaluations by a dentist who is familiar with this patient 
population.  
• Patients should be questioned about symptoms of heart 
failure, and a thorough physical examination should be done.  
• Additional evaluation with echocardiography is indicated in 
selected patients with positive findings from history and 
physical examination.  
• Patients should be instructed to seek immediate medical 
evaluation for persistent fever.  
http://circ.ahajournals.org/content/early/2015/09/15/CIR.0000000000000296 
Treatment 
(The ‘Endocarditis Team’) 
• IE is not a single disease, but rather may present with very 
different aspects depending on the first organ involved, the 
underlying cardiac disease (if any), the microorganism 
involved, the presence or absence of complications and the 
patient's characteristics, so no single practitioner will be able 
to manage and treat it. 
•  Very high level of expertise is needed from practitioners from 
several specialties, including cardiologists, cardiac surgeons, 
internal diseases specialists, microbiologists, neurologists, 
neurosurgeons, experts in coronary heart disease and others. 
• About half of the patients with IE undergo surgery during the 
hospital course. 
http://eurheartj.oxfordjournals.org/content/early/2015/08/28/eurheartj.ehv319 
Prognosis  
• Prognosis largely depends on whether or not complications 
develop.  
• If left untreated, IE is generally fatal.  
• Early detection and appropriate treatment of this uncommon 
disease can be lifesaving.  
• The overall mortality rate has remained stable at 14.5%. 
• Increased mortality rates are associated with increased 
age, infection involving the aortic valve, development of 
congestive heart failure, central nervous system (CNS) 
complications, and underlying disease such as diabetes mellitus 
• Acute endocarditis due to S aureus is associated with a high 
mortality rate (30-40%), except when it is associated with IV 
drug use. 
http://emedicine.medscape.com/article/216650-overview#a6 
Prophylaxis 
• There is no clinical evidence that it reduces the incidence of IE 
and there are negative effects (e.g. allergy and increased 
bacterial resistance) of taking antibiotics that may outweigh 
the benefits. 
• Antibiotics were historically commonly recommended to 
prevent IE in those with heart problems undergoing dental 
procedures (known as dental antibiotic prophylaxis) and in 
now days they are less commonly recommended for this 
procedure. 
• Preventive dental examination and therapy before surgery to 
repair heart valves or congenital heart lesions is 
recommended. 
http://www.merckmanuals.com/professional/cardiovascular-disorders/endocarditis/infective-endocarditis https://www.nice.org.uk/guidance/published?type=cg 
Key Points 
• Because the normal heart is relatively resistant to infection, endocarditis 
occurs when there is a predisposing abnormality of the endocardium. 
• Predisposing abnormalities include congenital heart defects, rheumatic 
valvular disease, bicuspid or calcific aortic valves, mitral valve prolapse, 
hypertrophic cardiomyopathy, prior endocarditis, and presence of a 
prosthetic valve. 
• Local cardiac consequences include myocardial abscess, conduction system 
abnormalities, and sudden, severe valvular regurgitation. 
• Systemic consequences include immune phenomena and septic emboli, 
which may affect any organ put particularly the lungs, kidneys, spleen, 
central nervous system (CNS), skin, and retina. 
• Diagnose using blood cultures and Duke criteria. 
• Treat with a prolonged course of antimicrobial therapy; surgery may be 
needed for mechanical complications or resistant organisms. 
• Give antimicrobial prophylaxis for patients at high risk of an adverse 
outcome from infective endocarditis. 
http://www.merckmanuals.com/professional/cardiovascular-disorders/endocarditis/infective-endocarditis 
Abbreviations  
ABE - acute bacterial endocarditis  
ACE - angiotensin converting 
enzyme 
BE - bacterial endocarditis  
CMR - cardiac magnetic resonance 
CNS – central nervous system 
CRP - C-reactive protein  
CT - computed tomography   
ECG - electrocardiogram  
ESR - erythrocyte sedimentation 
rate  
IDU - injection drug use  
IE - infective endocarditis  
HIV - human immunodeficiency 
virus 
  
MIC - minimum inhibitory 
concentration  
MRI - magnetic resonance imaging 
NBTE - non-bacterial thrombotic 
endocarditis 
LVADs - left ventricular assistive 
devices  
PK/PD - 
pharmacokinetic/pharmacodynamic  
SBE - subacute bacterial endocarditis   
TEE - transesophageal 
echocardiography 
TTE - transthoracic echocardiography 
PET -  positron emission tomography 
Diagnostic and treatment guidelines 
2015 ESC Guidelines for the management of infective 
endocarditis 
Infective Endocarditis in Adults: Diagnosis, Antimicrobial 
Therapy, and Management of Complications 
Prophylaxis against infective endocarditis: antimicrobial 
prophylaxis against infective endocarditis in adults and children 
undergoing interventional procedures 
Infective Endocarditis 
Infective Endocarditis 
Cardiac imaging in infectious endocarditis 
 
